Regulation of the calpain and ubiquitin-proteasome systems in a canine model of muscular dystrophy

Muscle and Nerve

Volumn 44, Issue 4, 2011, Pages 553-562

  Wadosky, Kristine M ^a   Li, Luge ^a   RodríGuez, Jessica E ^a   Min, Jin Na ^a   Bogan, Dan ^a   Gonzalez, Jason ^b   Patterson, Cam ^a   Kornegay, Joe N ^a   Willis, Monte ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Calpain; Heart; Muscular dystrophy; Proteasome; Skeletal muscle

Indexed keywords

ATROGIN 1; CALPAIN 1; CALPAIN 2; MESSENGER RNA; MUSCLE RING FINGER 1 PROTEIN; PROTEASOME; PROTEASOME SUBUNIT ACTIVATOR SUBUNIT 1; PROTEASOME SUBUNIT ALPHA TYPE 6; PROTEASOME SUBUNIT BETA TYPE 4; PROTEIN; PROTEIN MDM2; SUMO 1 PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG; UNCOORDINATED PHENOTYPE 4 PROTEIN; UNCOORDINATED PHENOTYPE 5 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOG; ENZYME ACTIVITY; FLUOROMETRY; HEART MUSCLE; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; TRANSCRIPTION REGULATION;

ANIMALS; CALPAIN; DISEASE MODELS, ANIMAL; DOGS; GENE EXPRESSION REGULATION; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MYOCARDIUM; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

EID: 80052880682     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.22125     Document Type: Article

References (59)

1. Kamper A, Rodemann HP. Alterations of protein degradation and 2-D protein pattern in muscle cells of MDX and DMD origin. Biochem Biophys Res Commun 1992;189:1484-1490.
2. Spencer MJ, Croall DE, Tidball JG. Calpains are activated in necrotic fibers from mdx dystrophic mice. J Biol Chem 1995;270:10909-10914.
3. Badalamente MA, Stracher A. Delay of muscle degeneration and necrosis in mdx mice by calpain inhibition. Muscle Nerve 2000;23:106-111.
4. Bonuccelli G, Sotgia F, Capozza F, Gazzerro E, Minetti C, Lisanti MP. Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice. Cell Cycle 2007;6:1242-1248.
5. Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman SE, et al. Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. Am J Pathol 2003;163:1663-1675.
6. Briguet A, Erb M, Courdier-Fruh I, Barzaghi P, Santos G, Herzner H, et al. Effect of calpain and proteasome inhibition on Ca2{thorn}-dependent proteolysis and muscle histopathology in the mdx mouse. FASEB J 2008;22:4190-4200.
7. Burdi R, Didonna MP, Pignol B, Nico B, Mangieri D, Rolland JF, et al. First evaluation of the potential effectiveness in muscular dystrophy of a novel chimeric compound, BN 82270, acting as calpaininhibitor and anti-oxidant. Neuromuscul Disord 2006;16:237-248.
8. Combaret L, Taillandier D, Voisin L, Samuels SE, Boespflug-Tanguy O, Attaix D. No alteration in gene expression of components of the ubiquitin-proteasome proteolytic pathway in dystrophin-deficient muscles. FEBS Lett 1996;393:292-296.
9. Gailly P, De Backer F, Van Schoor M, Gillis JM. In situ measurements of calpain activity in isolated muscle fibres from normal and dystrophin-lacking mdx mice. J Physiol 2007;582:1261-1275.
10. Gazzerro E, Assereto S, Bonetto A, Sotgia F, Scarfi S, Pistorio A, et al. Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies. Am J Pathol 2010;176:1863-1877.
11. Kumamoto T, Fujimoto S, Ito T, Horinouchi H, Ueyama H, Tsuda T. Proteasome expression in the skeletal muscles of patients with muscular dystrophy. Acta Neuropathol 2000;100:595-602.
12. Selsby JT, Pendrak K, Zadel M, Tian Z, Pham J, Carver T, et al. Leupeptin-based inhibitors do not improve the mdx phenotype. Am J Physiol Regul Integr Comp Physiol 2010;299:R1192-R1201.
13. Spencer MJ, Mellgren RL. Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology. Hum Mol Genet 2002; 11:2645-2655.
14. Spencer MJ, Tidball JG. Calpain concentration is elevated although net calcium-dependent proteolysis is suppressed in dystrophindeficient muscle. Exp Cell Res 1992;203:107-114.
15. Valentine BA, Winand NJ, Pradhan D, Moise NS, de Lahunta A, Kornegay JN, et al. Canine X-linked muscular dystrophy as an animal model of Duchenne muscular dystrophy: a review. Am J Med Genet 1992;42:352-356.
16. Cooper BJ, Winand NJ, Stedman H, Valentine BA, Hoffman EP, Kunkel LM, et al. The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature 1988;334:154-156.
17. Kornegay JN, Tuler SM, Miller DM, Levesque DC. Muscular dystrophy in a litter of golden retriever dogs. Muscle Nerve 1988;11:1056-1064.
18. Sharp NJ, Kornegay JN, van Camp SD, Herbstreith MH, Secore SL, Kettle S, et al. An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 1992;13:115-121.
19. Willis MS, Ike C, Li L, Wang DZ, Glass DJ, Patterson C. Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo. Circ Res 2007;100:456-459.
20. Kristiansen M, Deriziotis P, Dimcheff DE, Jackson GS, Ovaa H, Naumann H, et al. Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell 2007;26:175-188.
21. Kisselev AF, Goldberg AL. Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol 2005;398:364-378.
22. Min JN, Whaley RA, Sharpless NE, Lockyer P, Portbury AL, Patterson C. CHIP deficiency decreases longevity, with accelerated aging phenotypes accompanied by altered protein quality control. Mol Cell Biol 2008;28:4018-4025.
23. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-1708.
24. Li HH, Willis MS, Lockyer P, Miller N, McDonough H, Glass DJ, et al. Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins. J Clin Invest 2007;117:3211-3223.
25. Willis MS, Rojas M, Li L, Selzman CH, Tang RH, Stansfield WE, et al. Muscle ring finger 1 mediates cardiac atrophy in vivo. Am J Physiol Heart Circ Physiol 2009;296:H997-H1006.
26. Willis MS, Schisler JC, Li L, Rodriguez JE, Hilliard EG, Charles PC, et al. Cardiac muscle ring finger-1 increases susceptibility to heart failure in vivo. Circ Res 2009;105:80-88.
27. Matsuda R, Nishikawa A, Tanaka H. Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle. J Biochem 1995;118:959-964.
28. Sandri M, Minetti C, Pedemonte M, Carraro U. Apoptotic myonuclei in human Duchenne muscular dystrophy. Lab Invest 1998;78:1005-1016.
29. Tidball JG, Albrecht DE, Lokensgard BE, Spencer MJ. Apoptosis precedes necrosis of dystrophin-deficient muscle. J Cell Sci 1995;108: 2197-2204.
30. Tripathi V, Ali A, Bhat R, Pati U. CHIP chaperones wild type p53 tumor suppressor protein. J Biol Chem 2007;282:28441-28454.
31. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-299.
32. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
33. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-1245.
34. Nyamsuren O, Faggionato D, Loch W, Schulze E, Baumeister R. A mutation in CHN-1/CHIP suppresses muscle degeneration in Caenorhabditis elegans. Dev Biol 2007;312:193-202.
35. Barral JM, Epstein HF. Protein machines and self assembly in muscle organization. Bioessays 1999;21:813-823.
36. Desterro JM, Thomson J, Hay RT. Ubch9 conjugates SUMO but not ubiquitin. FEBS Lett 1997;417:297-300.
37. Sorokin AV, Kim ER, Ovchinnikov LP. Proteasome system of protein degradation and processing. Biochemistry (Mosc) 2009;74:1411-1442.
38. Goll DE, Neti G, Mares SW, Thompson VF. Myofibrillar protein turnover: the proteasome and the calpains. J Anim Sci 2008;86:E19-35.
39. Saez ME, Ramirez-Lorca R, Moron FJ, Ruiz A. The therapeutic potential of the calpain family: new aspects. Drug Discov Today 2006;11:917-923.
40. Willis MS, Schisler JC, Portbury AL, Patterson C. Build it up-tear it down: protein quality control in the cardiac sarcomere. Cardiovasc Res 2009;81:439-448.
41. Portbury AL, Willis MS, Patterson C. Tearin' up my heart: proteolysis in the cardiac sarcomere. J Biol Chem 2011;286:9929-9934.
42. Kwak J, Workman JL, Lee D. The proteasome and its regulatory roles in gene expression. Biochim Biophys Acta 2011;1809:88-96.
43. Willis MS, Patterson C. Into the heart: the emerging role of the ubiquitin-proteasome system. J Mol Cell Cardiol 2006;41:567-579.
44. Bukowska A, Lendeckel U, Bode-Boger SM, Goette A. Physiologic and pathophysiologic role of calpain: implications for the occurrence of atrial fibrillation. Cardiovasc Ther (in press).
45. Testa U. Proteasome inhibitors in cancer therapy. Curr Drug Targets 2009;10:968-981.
46. Tamura D, Arao T, Tanaka K, Kaneda H, Matsumoto K, Kudo K, et al. Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition. Cancer Sci 2010;101:1403-1408.
47. Fu HY, Minamino T, Tsukamoto O, Sawada T, Asai M, Kato H, et al. Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition. Cardiovasc Res 2008;79:600-610.
48. Tsukamoto O, Minamino T, Okada K, Shintani Y, Takashima S, Kato H, et al. Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice. Biochem Biophys Res Commun 2006;340:1125-1133.
49. Tang M, Li J, Huang W, Su H, Liang Q, Tian Z, et al. Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts. Cardiovasc Res 2010;88:424-433.
50. Takamatsu H, Yamashita T, Kotani T, Sawazaki A, Okumura H, Nakao S. Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma. Int J Hematol 2010;91:903-906.
51. Lendeckel U, Goette A. Calpain in atrial fibrillation: friend or foe?: editorial to: "anti-apoptotic effects of a calpain inhibitor on cardiomyocytes in a canine rapid atrial fibrillation model" by Yue Li et al. Cardiovasc Drugs Ther 2009;23:339-340.
52. Finsterer J, Stollberger C. The heart in human dystrophinopathies. Cardiology 2003;99:1-19.
53. Takami Y, Takeshima Y, Awano H, Okizuka Y, Yagi M, Matsuo M. High incidence of electrocardiogram abnormalities in young patients with duchenne muscular dystrophy. Pediatr Neurol 2008;39:399-403.
54. Chenard AA, Becane HM, Tertrain F, de Kermadec JM, Weiss YA. Ventricular arrhythmia in Duchenne muscular dystrophy: prevalence, significance and prognosis. Neuromuscul Disord 1993;3:201-206.
55. Fauconnier J, Thireau J, Reiken S, Cassan C, Richard S, Matecki S, et al. Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy. Proc Natl Acad Sci USA 2010;107:1559-1564.
56. Megeney LA, Kablar B, Perry RL, Ying C, May L, Rudnicki MA. Severe cardiomyopathy in mice lacking dystrophin and MyoD. Proc Natl Acad Sci USA 1999;96:220-225.
57. Hsu DT. Cardiac manifestations of neuromuscular disorders in children. Paediatr Respir Rev 2010;11:35-38.
58. Romfh A, McNally EM. Cardiac assessment in Duchenne and Becker muscular dystrophies. Curr Heart Fail Rep 2010;7:212-218.
59. Kornegay JN, Cundiff DD, Bogan DJ, Bogan JR, Okamura CS. The cranial sartorius muscle undergoes true hypertrophy in dogs with golden retriever muscular dystrophy. Neuromuscul Disord 2003;13: 493-500.